This study aims to evaluate the safety, tolerability and efficacy of SHR-7787 in combination with other anti-tumor drugs in patients with malignant solid tumors.
Ability to understand and voluntarily agrees to participate by giving written informed consent for the study;
Patients with histologically or cytologically confirmed unresectable solid tumors;
At least one measurable lesion was identified per RECIST 1.1;
Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1;
Patients with known active central nervous system (CNS) metastases;
History of other malignancy within the past 5 years, with exceptions defined in the protocol;
Patients with uncontrolled cancer pain;
Patients with serious cardiovascular and/or cerebrovascular diseases;
8
Treatment groupsSee each treatment group below.